Business and Finance

Per the deal, DKSH inherits the specialty pharma company’s Asia-Pacific medication portfolio.

In deal that has the potential to reach $1.1 billion, Otsuka aims to grow its drug pipeline, specifically in the field of rare and autoimmune diseases.

The parties’ combined portfolio help tackle the rising demand for advanced cell and gene therapies.

Gallagher’s 2024 US Physical & Emotional Wellbeing Report outlines ways to meeting evolving needs in the workforce.

The partnership—which features a $150 million investment—is also centered around vaccine development in the respiratory and immunology space.

The acquisition provides Ardian with greater insight into the life science industry.

The parties will continue to create new candidate therapies for the treatment of a severe form of TUBB4A leukodystrophy.

The deal exponentially grows the CDMO’s biopharma capabilities.

In a transaction valued at $250 million, the deal makes Grünenthal the new owner of Movantik, which treats OIC in adult patients with chronic non-cancer pain.

The financial commitment includes a pair of expansion plans occurring in the United States and Europe.

The clinical supply facility undergoes a $25 million expansion, welcoming 32,000 more square feet of temperature-controlled storage.

The construction of 100,000 square-foot facility will boost the site's filling capacity to 140 million units per year.

The acquisition in the ophthalmology space features a $1.3 billon cash payment, with the potential for an additional $1.7 billion if various milestones are met.

The merger combines the companies under the MedPharma name, creating a topical and transepithelial CDMO in the process.

The investment is expected to help enhance the company temperature-controlled services in the Netherlands, France, Italy, and Hungary.

The Stelara biosimilar will be commercialized by Sandoz, and is expected to launch by February 2025 for multiple indications, including for the treatment of adult patients with active psoriatic arthritis.

The deal provides the CDMO with ownership of the Lexington facility, allowing for late-phase and commercial gene therapy development and manufacturing of a branded severe Hemophilia B product.

Following the evaluation, the company will decide whether it wants to move forward with the IDMO’s automated, end-to-end, cell therapy manufacturing platform.

The company’s latest investment—featuring new cGMP suites at its Devens, MA plant—is valued at $30 million.

The North Carolina project adds 1.4 million square feet of dedicated production space for aseptic manufacturing and finished production processes.

The company acquires Alimera Sciences for $381 million upfront, while establishing its interest in ophthalmology.

The acquisition of the 87,000 square-foot Camden, MD plant provides the CDMO with the ability to offer clinical and commercial non-viral aseptic fill-finish services on four fill lines.

Deal will target neurological diseases, featuring an initial payment of $42 million for Ascidian and up to $1.8 billion in milestone payments/royalties.

An analysis of the general medicine portion of the pharmacy market amid ensuing challenges.

Financial commitment will go toward expanding the CDMO’s integrated antibody-drug conjugate services.

The deal grows it pipeline, powered by panCAR programs in autoimmune disease and oncology.

With the acquisition, Merck’s US and Canada life science business aims to further increase its viral vector manufacturing capabilities.

The deal features felzartamab, an investigational anti-CD38 monoclonal antibody, whose clinical outcomes have shown potential to tackle various immune-mediated diseases.

The agreement is expected to focus on cell manufacturing processes, with potential for sharing tech with academia, startups.

The facility, company says, will be its first that covers end-to-end ADC production.